Table 1 Cutaneous reactions associated with dipeptidyl peptidase-4 inhibitors reported in RCTs, cohorts, and case series. (bullous pemphigoid not included)
No. | First author, year | Type of skin reaction | Culprit drug | Sample size | Prevalence | Comorbidities | Concomitant Medications |
|---|---|---|---|---|---|---|---|
RCTs | |||||||
1. | Yosuke Takamiya,2019 [9] | Pruritus Non-specified skin rash | Teneligliptin | 162 | Pruritis & rash: 1% & 0.5% respectively | – | – |
2. | M.A. Banerji,2010 [10] | Non-specified skin rash | Vildagliptin | 2627 | 0.4% | Renal impairment | Metformin |
3. | R E Pratley,2009 [11] | Pruritus | Alogliptin | 585 | 1.5% & 3% in the Alogliptin 12.5 mg and 25 mg group respectively | – | – |
4. | M A Nauck,2009 [12] | Pruritus, Eczematoid dermatitis | Alogliptin | 420 | Dry skin & Pruritis 1.2% Rash 2.1% Eczema 1.0% | – | Metformin |
5. | Ralph A DeFronzo,2008 [13] | Pruritus | Alogliptin | 420 | 12.5% | N/A | – |
Cohort | |||||||
6. | Yuya Nakamura,2012 [14] | Exanthematous drug eruption | Alogliptin | 16 | 6% | Renal failure | Hemodialysis |
Case series | |||||||
7. | Shrey Desai,2010 [15] | SJS, TEN Angioedema, Anaphylaxis, Vasculitis | Sitagliptin | 48 | SJS, TEN:54% Angioedema: 9% Anaphylaxis: 31% Vasculitis:6% | – | – |